Gliclazide 80 mg (Generic)

Product Overview

Gliclazide 80 mg is a generic oral hypoglycemic agent manufactured by Panacea Biotech Ltd. It belongs to the sulfonylurea class and is indicated for the management of Type 2 diabetes mellitus. Each strip contains 15 tablets, and the product is available in pack sizes of 60, 90, or 120 tablets. The medication is shipped within 6 to 15 days, making it a convenient option for patients seeking reliable glycemic control.

What is Gliclazide 80 mg

Gliclazide works by stimulating the pancreatic beta‑cells to release insulin, thereby lowering blood glucose levels. It is chemically identical to the branded sulfonylurea but is offered at a cost‑effective price point. According to the MedlinePlus database, gliclazide is classified as a second‑generation sulfonylurea with a prolonged duration of action, allowing once‑daily dosing when titrated appropriately.

Uses and Benefits

The primary use of gliclazide 80 mg is to improve glycemic control in adults with Type 2 diabetes who have not achieved target HbA1c levels through diet and exercise alone. Clinical studies cited by the NIH demonstrate that sulfonylureas like gliclazide reduce fasting plasma glucose and post‑prandial glucose spikes, decreasing the risk of microvascular complications such as retinopathy and nephropathy. Additional benefits include:

• Improved insulin secretion in response to meals
• Convenient once‑daily dosing
• Compatibility with metformin and other oral agents
• Proven track record in long‑term cardiovascular outcome trials

How It Works

Gliclazide binds to the sulfonylurea receptor (SUR1) on the surface of pancreatic beta‑cells, causing closure of ATP‑sensitive potassium channels. This leads to depolarization of the cell membrane, influx of calcium, and subsequent release of insulin. The drug’s effect is glucose‑dependent, meaning that it stimulates insulin release only when blood glucose is elevated, which reduces the likelihood of severe hypoglycemia compared with earlier sulfonylureas.

Dosage Guidelines

Initial therapy typically starts with 40 mg taken once daily with breakfast, or 80 mg taken every other day, depending on the patient’s renal function and comorbidities. The dose may be titrated upward by 40 mg at intervals of 1–2 weeks, not exceeding 160 mg per day. Patients should be instructed to take the tablet with food to minimize gastrointestinal upset. Dose adjustments are required in cases of moderate to severe hepatic impairment, as recommended by the FDA prescribing information. Always monitor blood glucose regularly and consult a healthcare professional before making any changes.

Side Effects

Like all medications, gliclazide can cause adverse effects. The most common side effects reported in clinical practice include:

• Hypoglycemia, especially when combined with other glucose‑lowering agents
• Weight gain
• Gastrointestinal discomfort such as nausea or abdominal pain
• Skin reactions like rash or pruritus

Rare but serious adverse events may involve hepatic enzyme elevations or severe hypoglycemia requiring emergency intervention. If any of these symptoms occur, discontinue use and seek medical attention promptly.

Warnings and Precautions

Patients should be aware of several important precautions before initiating gliclazide therapy:

• Do not use if allergic to gliclazide or any component of the formulation.
• Avoid use in patients with type 1 diabetes or diabetic ketoacidosis.
• Use with caution in individuals with severe renal impairment (eGFR < 30 mL/min/1.73 m²) due to increased hypoglycemia risk.
• Pregnant or breastfeeding women should consult a physician, as safety data are limited.
• Regular monitoring of liver function tests is advised, particularly in patients with pre‑existing hepatic disease.

For comprehensive guidance, refer to the drug label on Drugs.com or consult a qualified healthcare provider.

FAQs

1. Can gliclazide be taken with other diabetes medications? Yes, it is often combined with metformin or DPP‑4 inhibitors, but dosage adjustments are necessary to avoid hypoglycemia.
2. How long does it take to see a reduction in blood glucose levels? Most patients experience a measurable drop in fasting glucose within 1–2 weeks of starting therapy, with maximal effect seen after 4–6 weeks.
3. Is gliclazide safe for elderly patients? Elderly individuals may be more sensitive to hypoglycemia; a lower starting dose and close glucose monitoring are recommended.
4. What should I do if I miss a dose? Take the missed dose as soon as remembered if it is within 6 hours of the scheduled time; otherwise, skip it and resume the regular schedule.
5. Are there any dietary restrictions? No specific foods must be avoided, but consistent carbohydrate intake helps maintain stable glucose levels.

For additional information on diabetes management, reputable resources such as the NIH, FDA, and MedlinePlus provide evidence‑based guidance.

Related Products

• Okamet 500 Mg (Metformin)
• Pangraf 0.25 mg (Tacrolimus)
• Pangraf 0.5mg (Tacrolimus)
• Pangraf 1mg (Tacrolimus)
• Pangraf (Tacrolimus)
• Tacrolimus 0.25mg (Generic)
• Pangraf 2mg (Tacrolimus)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)